期刊
CHINESE MEDICAL JOURNAL
卷 135, 期 4, 页码 393-399出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CM9.0000000000001929
关键词
IL-2; IL-15; IL-10; IL-18; Melanoma; Immunotherapy
资金
- National Defense Science and Technology Excellence Youth Talent Foundation of China [2018-JCJQ-ZQ-006]
- National Natural Science Foundation of China [82103379]
This article introduces the use of ILs to modulate the immune system in cancer treatment and discusses their application in the treatment of melanoma. It also mentions the potential synergy between ILs and immune checkpoint inhibition for better clinical outcomes.
Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据